Adult Dosing

Psoriasis vulgaris (Ointment)

• Apply ointment daily to affected area and rub for up to 4 wks
• Max 100g/wk

Psoriasis vulgaris (Suspension)

• Apply suspension daily to affected area and rub for up to 2 wks
• Max 100g/wk
• Note: Limit treatment area to 30% body surface area

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Treatment of psoriasis vulgaris

• Hypersensitivity to any of the ingredients of the product
• Calcium metabolism disorders
• Erythrodermic psoriasis
• Exfoliative psoriasis
• Pustular psoriasis
• Skin atrophy at site

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Do not use on face, axillae, groin, or atrophic skin
• Systemic absorption of topical corticosteroids are associated with reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria
• Use of more than one corticosteroid-containing product at the same time is associated with increased total systemic glucocorticoid exposure
• Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy
• Periodically evaluate patients receiving a higher dose of a potent topical steroid to a large surface for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. On presence of HPA axis suppression make an attempt to discontinue the drug, to reduce the frequency of application, or to substitute with a less potent steroid. Recovery from HPA axis function is generally prompt and complete upon withdrawal of this drug
• Children are more susceptible to systemic toxicity due to their larger skin surface to body mass ratios
• Chronic use may interfere with the growth and development of children
• On occurrence of irritation discontinue topical corticosteroids and institute appropriate therapy
• Use appropriate antifungal or antibacterial agent in the presence of dermatological infections
• On failure of occurrence of prompt favorable response discontinue corticosteroid until the infections are adequately controlled

Caution: Use cautiously in

• Severe renal impairment
• Severe hepatic impairment
• Pediatrics
• Skin infections

Supplemental Patient Information

• Avoid contact with the eyes
• Advise patients to consult their physician on any signs of local adverse reactions

Pregnancy Category:C

Breastfeeding: Topical betamethasone has not been evaluated during breastfeeding. Unlikely that short-term application of would pose a risk to the breastfed infant. Use the least potent drug on the smallest area of skin possible. Ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Use lower potency corticosteroids on the nipple or areola where the infant could directly ingest the drugs from the skin. Apply only water-miscible cream or gel products to the breast because ointments may expose the infant to high levels of mineral paraffins via licking. Wiped off any topical corticosteroid prior to nursing if it is applied to the breast or nipple area. Safety unknown of calcipotriene; however, minimal systemic absorption following topical application. it would not be expected to cause any adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 19 February 2011). Manufacturer advises caution.

• DERM: Pruritus, headache, psoriasis, rash scaly, erythema, psoriasis exacerbation, striae, acneiform eruption, perioral dermatitis, miliaria
• EENT: Nasopharyngitis
• RESP: Upper respiratory tract infection
• LOCAL: Skin irritation, pain, burning sensation, folliculitis
• ENDO: HPA axis suppression, cushing syndrome, hyperglycemia
• CNS: Intracranial hypertension
• MISC: Influenza, tumorigenicity

betamethasone dipropionate

• Glucocorticoid; precise mechanism of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; controls the biosynthesis of prostaglandins and leukotrienes and exhibits multiple glucocorticoid and mineralocorticoid effects
• Minimal absorbtion
• Metabolized by liver; CYP450: Unknown
• Excreted in urine
• Half-life: 36-54 hr

calcipotriene

• Synthetic vitamin D3 analog; exact mechanism of action unknown
• 6% systemic absorption
• Metabolized by liver; CYP450: Unknown
• Primarily excreted in bile; minimally in urine
• Half-life: Unknown

US Trade Name(s)

• Taclonex
• Taclonex Scalp

US Availability

betamethasone dipropionate/calcipotriene (generic)

• OINT: 0.064%/ 0.005%

Taclonex (betamethasone dipropionate/calcipotriene)

• OINT: 0.064%/ 0.005%

Taclonex Scalp (betamethasone dipropionate/calcipotriene)

• SUSP: 0.064%/ 0.005%

Canadian Trade Name(s)

• Dovobet
• Xamiol

Canadian Availability

Dovobet (betamethasone dipropionate/calcipotriol)

• OINT: 0.05%/ 50 mcg/g

Xamiol (betamethasone dipropionate/calcipotriol)

• GEL: 0.05%/ 50 mcg/g

UK Trade Name(s)

• Dovobet
• Xamiol

UK Availability

Dovobet (betamethasone dipropionate/calcipotriol)

• OINT: 0.05%/ 50 mcg/g

Xamiol (betamethasone dipropionate/calcipotriol)

• GEL: 0.05%/ 50 mcg/g

Australian Trade Name(s)

• Dovobet

Australian Availability

Dovobet (betamethasone dipropionate/calcipotriol)

• OINT: 0.05%/ 50 mcg/g

Dermatologic

Dermatologic Topical Agents

Antipsoriatics

Rheumatologic

Dermatologic Topical Agents

Antipsoriatics

Pricing data from www.DrugStore.com in U.S.A.

• Taclonex 0.005-0.064 % OINT [Tube] (LEO PHARMA INC)
  100 % = $884.96
  300 % = $2579.08
• Taclonex Scalp 0.005-0.064 % SUSP [Bottle] (LEO PHARMA INC)
  60 % = $530.98
  180 % = $1577.89
• Taclonex 0.005-0.064 % OINT [Tube] (LEO PHARMA INC)
  60 % = $573
  180 % = $1591.01

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.